A Phase II Trial of Irinotecan in Patients with Previously Untreated Advanced Esophageal and Gastric Adenocarcinoma
Peter C. Enzinger(Dana-Farber Cancer Institute), Charles S. Fuchs(University of Southern California), Matthew H. Kulke(Moffitt Cancer Center), Michele Vincitore(Dana-Farber Cancer Institute), Ann Michelini(Dana-Farber Cancer Institute), Craig C. Earle(Canadian Partnership Against Cancer), Robert J. Mayer(Applied Natural Sciences), David P. Ryan(East Carolina University), Jeffrey W. Clark(Massachusetts General Hospital), Haesook Kim(Dana-Farber Cancer Institute)
Cited by 73
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Fusobacterium nucleatum Potentiates Intestinal Tumorigenesis and Modulates the Tumor-Immune Microenvironment
|Cell Host & Microbe|2013|2.7k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k